Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Dollar index (DXY) slipped about 20 points in the short term; USD/JPY fell about 70 points.
2026-09-22
Dollar index (DXY) slipped about 20 points in the short term; USD/JPY fell about 70 points.
Back
Other News
2026-09-22
SpaceXAI's Grok Bot had 418,000 weekly active users as of Sept. 14, up 24% week-on-week, after launching in mid-August, presentation materials showed. The AI agent is pitched to compete with Anthropic PBC and OpenAI and is designed to act like an aro
SpaceXAI's Grok Bot had 418,000 weekly active users as of Sept. 14, up 24% week-on-week, after launching in mid-August, presentation materials showed. The AI agent is pitched to compete with Anthropic PBC and OpenAI and is designed to act like an around-the-clock employee rather than a chatbot—handling emails, updating sales databases, processing invoices, coordinating workflows and filing software bug reports. The user figures indicate only modest initial demand.
2026-09-23
According to the Financial Times, Novo Nordisk (NVO.N) is not ruling out upgrading its New York listing, a move aimed at boosting the Danish weight-loss drug manufacturer's visibility in the US market. This follows a similar move by its British rival
According to the Financial Times, Novo Nordisk (NVO.N) is not ruling out upgrading its New York listing, a move aimed at boosting the Danish weight-loss drug manufacturer's visibility in the US market. This follows a similar move by its British rival AstraZeneca earlier this year.
Chat with us
, powered by
LiveChat